Anti-Diabetic Therapy and Bone Fragility Achieving favorable control of blood glucose may be effective in preventing fractures through keeping appropriate bone turnover, because improvement of blood glucose restores decreased markers of bone formation [1,2]. However, some antidiabetic agents have been reported to influence bone turnover negatively. Large-scale surveys indicated that insulin secretagogue and metformin were not associated with the risk of fracture, rather reduce it [3-6].
Several studies showed that patients with insulin therapy have a higher risk of fractures than those with other antidiabetic therapy [3-8], which is considered as an adverse effect of poor blood glucose control. Glucose-dependent insulinotropic polypeptide (GIP) [9, 10] and Glucagon-like peptide-1 (GLP-1) [11,12], which are called incretins, have been reported to increase bone mass in genetically…
